Novo Nordisk: presents string of data at diabetes congress

(CercleFinance.com) - Denmark's Novo Nordisk has presented an entire series of data on its product portfolio at the American Diabetes Association's sessions which are currently taking place in Orlando.


The drugmaker said oral semaglutide, its experimental once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type-2 diabetes, according to findings from a phase 3a trial.

Another compound belonging to the company, Tresiba, demonstrated significantly improved blood sugar control and lower rates of hypoglycaemia versus insulin glargine U300 in real-world evidence study.

In addition, Novo's Ozempic (semaglutide) provided greater weight reductions vs Lilly's dulaglutide in adults with type 2 diabetes, regardless of baseline body mass index.

Finally, significant blood sugar improvement was obtained with Novo Nordisk 's Xultophy compared to insulin glargine U-100 when used as add-on to oral diabetes medications, the group said.

The Copenhagen-based Novo Nordisk shares were up 1% at 304 Danish kronor after these results.

Copyright (c) 2018 CercleFinance.com. All rights reserved.